Avita Medical (OTCMKTS:AVMXY) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Friday.

Shares of Avita Medical (OTCMKTS:AVMXY) traded up $0.06 on Friday, hitting $1.07. The stock had a trading volume of 40,812 shares, compared to its average volume of 44,698. Avita Medical has a one year low of $0.75 and a one year high of $2.07.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/03/avita-medical-avmxy-raised-to-sell-at-valuengine.html.

About Avita Medical

Avita Medical Limited is a medical technology company. The principal activities of the Company are the commercialization of its regenerative product. The Company has three segments: the Asia Pacific region; the Americas, including Canada, and the Europe, Middle East and Africa (EMEA) region. It develops and distributes regenerative products for the treatment of a range of wounds, scars and skin defects.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Avita Medical Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avita Medical Ltd and related companies with MarketBeat.com's FREE daily email newsletter.